Ampio Pharmaceuticals, Inc. (AMPE)
Ampio Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Englewood, CO, US. The stock last traded at $0.18, up 0.00% on the session, giving a market capitalisation of $207,884. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of 0.0%. Its beta of 6.30 implies it has historically moved more than the broad market.
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
Ampio Pharmaceuticals, Inc. is most often compared with the following Healthcare names: